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Abstract
Background: A genome-wide association study (GWAS) typically involves examining representative SNPs in individuals from
some population. A GWAS data set can concern a million SNPs and may soon concern billions. Researchers investigate the
association of each SNP individually with a disease, and it is becoming increasingly commonplace to also analyze multi-SNP
associations. Techniques for handling so many hypotheses include the Bonferroni correction and recently developed
Bayesian methods. These methods can encounter problems. Most importantly, they are not applicable to a complex multi-
locus hypothesis which has several competing hypotheses rather than only a null hypothesis. A method that computes the
posterior probability of complex hypotheses is a pressing need.
Methodology/Findings: We introduce the Bayesian network posterior probability (BNPP) method which addresses the
difficulties. The method represents the relationship between a disease and SNPs using a directed acyclic graph (DAG) model,
and computes the likelihood of such models using a Bayesian network scoring criterion. The posterior probability of a
hypothesis is computed based on the likelihoods of all competing hypotheses. The BNPP can not only be used to evaluate a
hypothesis that has previously been discovered or suspected, but also to discover new disease loci associations. The results
of experiments using simulated and real data sets are presented. Our results concerning simulated data sets indicate that
the BNPP exhibits both better evaluation and discovery performance than does a p-value based method. For the real data
sets, previous findings in the literature are confirmed and additional findings are found.
Conclusions/Significance: We conclude that the BNPP resolves a pressing problem by providing a way to compute the
posterior probability of complex multi-locus hypotheses. A researcher can use the BNPP to determine the expected utility of
investigating a hypothesis further. Furthermore, we conclude that the BNPP is a promising method for discovering disease
loci associations.
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Introduction
The advent of high-throughput technologies has enabled
genome-wide association studies (GWAS). A GWAS can involve
examining a million representative single-nucleotide polymor-
phisms (SNPs) in individuals from some population. Often GWAS
are conducted on cases and controls, where cases are individuals
with a disease and controls are individuals without the disease. We
then investigate the statistical association of each SNP with the
disease. In doing so, a million hypotheses (disease-SNP relation-
ships) or more may be investigated.
GWA studies provide researchers unprecedented opportunities
to investigate the complex genetic basis of diseases such as cancer.
For example, GWAS have indicated that alleles in the FGFR2 gene
are associated with sporadic postmenopausal breast cancer [1];
that five loci are associated with breast cancer including the
plausible causative genes FGFR2, TNRC9, MAP3K1, and LSP1 [2];
and that GAB2 alleles may modify Alzheimer’s risk in APOE e4
carriers [3]. Studies investigating SNPs in tumorous and non-
tumorous tissue have revealed somatic mutations possibly
associated with cancer. For example, recent studies showed eight
genes somatically mutated in glioblastoma tumors [4], and 26
genes somatically mutated in lung adenocarcinoma [5]. The 1000
Genomes Project plans to produce sequence coverage that will
extend the list of human genetic variation [6], and gene-
environment-wide association studies are emerging [7], both of
which will increase the number of hypotheses investigated. Epistasis
is the interaction between two or more genes to affect a phenotype
such as disease susceptibility. Biologically, epistasis likely arises
from physical interactions occurring at the molecular level.
Statistically, epistasis refers to an interaction between multiple
loci such that the net affect on phenotype cannot be predicted by
simply combining the effects of the individual loci. Researchers
now believe that epistasis may account for a significant portion of
the dark matter of genetic risk for disease [8], and it is becoming
increasingly commonplace for researchers to investigate epistasis
using GWAS data sets [9,10], which dramatically increases the
number of hypotheses investigated. For example, if we only
PLoS ONE | www.plosone.org 1 August 2011 | Volume 6 | Issue 8 | e22075
considered all 2-SNP interactions when there are 500,000 SNPs,
we would have 1: 25|1011 additional hypotheses.
These exciting possibilities for learning potential disease risk
from high-dimensional data sets presents us with a challenge -
namely how do we analyze and interpret our results when there
are possibly billions of hypotheses? The hypothesis testing involved
here is substantially different than that involved in a typical
analysis where we might analyze the effect of a new drug. In this
latter case, we are analyzing only one hypothesis, and the drug has
a fairly high prior probability of being effective, otherwise the
study would not have been considered. In discovery studies
involving many hypotheses, each hypothesis has a very low prior
probability.
Historically, the most common strategy for handling this
multiple hypotheses testing problem has been to control type I
error (false discovery) by using the Bonferroni correction to
constrain the family-wise error rate. For example, the results in [3]
were reported as being significant with Bonferroni correction.
However, these corrected results often fail to duplicate across
studies [8]. More recently developed techniques include the false
discovery rate [11], false positive report probability [12], and
Bayesian false discovery probability [13].
These methods all have the same purpose, namely to provide us
with a way to decide which SNPs to ‘‘flag as noteworthy for further
investigation’’ [13]. A difficulty with these methods is that they are
not applicable to a complex multi-locus hypothesis, which has
several competing hypotheses rather than only a null hypothesis.
However, as mentioned above, it is becoming increasingly
commonplace to investigate gene-gene interactions. So, a method
that computes the posterior probability of a complex multi-locus
hypothesis (and thereby flags the SNPs in the hypothesis as
noteworthy) is a pressing need. In the Methods section we present
a fully Bayesian method called the Bayesian network posterior
probability (BNPP) method that is able to handle multi-locus
hypotheses by computing the posterior probability of a hypothesis;
it does so by assigning prior probabilities over all the hypotheses
and computing the likelihoods of specialized Bayesian network
structures [14], as explained below. The Results section shows
results of experiments illustrating the effectiveness of the BNPP at
both evaluation and discovery, using both simulated and real data
sets. In the remainder of this section we briefly review current
methods and point out difficulties that they encounter.
When testing multiple hypotheses as in a GWAS, one of the
hypotheses is likely to have a significant p-value by chance. As a
result, researchers often use the Bonferroni correction to control the
family-wise error rate by multiplying the p-value by the number of
hypotheses n. For example, if p~2:1|10{7 for a given SNP-
outcome association and n~500, 000, then the Bonferroni-
corrected p-value is p|n~500, 000|2:1|10{7~0:105. This
result would not be deemed significant by most standards, and the
null hypothesis would not be rejected. A related correction is the
Sˇida´k correction, which is 1{(1{p)n.
Wakefield [13] notes that in the case of a GWAS the Bonferroni
correction will often be an overly conservative procedure since at
least in the current early stages of such studies we are more
concerned with avoiding missed associations, and making some
false discoveries is not too high a cost to pay to find real
associations. Neapolitan [15] has a more fundamental problem
with the Bonferroni correction. He argues that it is a misguided
practice, and that the significance we attach to a result concerning
a particular hypothesis cannot depend on the number of
hypotheses we happen to test along with that hypothesis.
Regardless of one’s stance on this matter, there are clear
difficulties in applying the Bonferroni correction in GWA studies.
Suppose that one study investigates 100, 000 SNPs while another
investigates 500, 000 SNPs. Suppose further that the data
concerning a particular SNP and the disease is identical in the
two studies. Due to the different corrections, that SNP could be
reported as significant in one study but not the other. Yet the data
concerning the SNP is identical in the two studies. As noted
earlier, in GWAS results are often not duplicated across studies.
One reason may be the practice of using different corrections
across different studies. Initially GWAS data were analyzed by
investigating only 1-SNP models (hypotheses). We use the terms
‘‘model’’ and ‘‘hypothesis’’ interchangeably. Strictly speaking, the
hypothesis is the statement that the model is correct.
So if there were 500, 000 SNPs, there would be 500, 000
hypotheses. Based on these studies, quite a few results have been
reported as significant with correction [3,16–18]. It is becoming
increasingly popular to also investigate 2-SNP models in the effort
to identify epistatic relationships [8–10]. As mentioned above, if
there are 500, 000 SNPs, there are about 1: 25|1011 2-SNP
models. If the researchers who previously reported significant
results had also investigated the 2-SNP models, the corrections
would have been based on many more hypotheses and the results
likely would not have been reported as significant.
Realizing these problems, some researchers [17,19] have
suggested that we uniformly use a Bonferroni correction assuming
106 independent tests in GWA studies. This value was arrived at
based on assuming only 1-SNP models are tested. If this were
done, the problem concerning using different corrections when
analyzing 1-SNP models in different studies would be addressed,
but the problem of analyzing 1-SNP models along with 2-SNP
models would not. We could correct the significance of a 1-SNP
model assuming 106 tests, and then perhaps we could correct the
significance of a 2-SNP model assuming a much larger number of
tests. However, even if we did all this we would still have the
problem identified by Wakefield [13] concerning the correction
being overly conservative, and the problem that we have ignored
the probability of the data given the alternate hypothesis (power).
Benjamin and Hochberg [11] concluded that a desirable error
rate to control is the expected proportion of errors among the
rejected null hypotheses, which they termed the false discovery rate
(FDR). That is, the FDR is E(V/R), where E denotes expected
value, R is the number of null hypotheses rejected and V is the
number of true null hypotheses rejected (Recall that we make a
discovery when we reject a null hypothesis). They prove the
following theorem, which enables us to control the FDR in
practice: Suppose we have n hypotheses with corresponding p-
values p1ƒp2ƒ . . .ƒpn. Denote by Hi the null hypothesis
corresponding to pi. Let
k be the largest i such that piƒ
i
n
q:
Then if we reject H1,H2, . . . ,Hk, the FDR is #q.
Storey [20] gave the FDR a Bayesian interpretation, showed
that the E(V/R|R.0) (called the positive FDR) does not depend on
n, and defined the q-value. Storey and Tibshirani [21] develop an
empirical method for estimating the q-value from the observed
distribution of p-values.
Storey et al. [22] developed a method that computes the
posterior probability that a locus is in the true model given the
data, without ever estimating the entire true model. However, this
method is applicable to the situation in which we are investigating
many phenotype traits simultaneously rather than a single trait.
The FDR was used to correct for multiple comparisons in this
method.
A Bayesian Method for Disease Loci Evaluation
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The next two methods discussed concern the following analysis.
We test H0 : h~0 vs. H1 : hw0 where h is the log odds ratio. For
example, if H1 is the hypothesis that a particular SNP S is
associated with disease D,
h~ln
Odds(D~1jS~11)
Odds(D~1jS=11)
 
,
where by D= 1 we mean the disease is present, and by S~11 we
mean that an individual has two copies of the mutant allele 1. We
have assumed in this example that the wild type is dominant. The
model assumes a test statistic T with E(T)~h. For example, we
may fit a logistic regression model so that T is the maximum
likelihood estimate of the log odds ratio.
The false positive report probability (FPRP) [12] is defined as follows:
FPRP~P(H0jData)~ p|P(H0)
p|P(H0)zpower|P(H1)
,
where p is the p-value, the Data are assumed to be the result that
jT jwtobs where tobs is the observed value of T, and
power~P(Datajh1) is evaluated at a pre-specified h1.
There are a number of difficulties with this method:
1. Information is being lost by considering the data as being the
result that jT jwtobs rather than the point value (tobs) we
observed.
2. How do we decide on a particular value of h1? Perhaps we
should consider a range of values.
3. The odds ratio only considers two possibilities, either a
condition is present or it is not. However, we may want to
model that there could be a different effect on disease for each
of the three values a SNP can obtain.
4. We can only consider a null hypothesis H0 and an alternative
hypothesis H1. However, if we model 2-SNP, 3-SNP models,
etc., there are several competing models (hypotheses) besides
the one whose probability we are computing and each has a
different likelihood. This issue is discussed in more detail in the
Methods section.
As an alternative to the FPRP, Wakefield [13] developed the
Bayesian false discovery probability (BFDP) which addresses several of
the difficulties just presented. We do not go into its details here,
but only mention that it does not attend to Difficulties 3 and 4.
A Bayesian method was used to compute the strength of
association of a finding obtained using GWAS data in the
Wellcome Trust Case Control Consortium study [23]. This
method identified the following three hypotheses concerning the
association of a single SNP with the disease:
1. H0 denotes a model with no association with the disease.
2. H1 denotes a two-parameter model with an additive effect on
the log-odds scale. That is, the log-odds for the ith individual is
mzcZi
where Zi is the genotype (codes as 0, 1, or 2), m is the baseline
odds, andci is the increase in odds for every copy of the allele
coded as 1.
3. H2 denotes a three-parameter model with an additive effect on
the log-odds scale.
The Bayes factor for Hi versus H0 is
P(DatajHi)
P(DatajH0) ,
where
P(DatajHi)~
ð
P(Datajhi,Hi)P(hijHi)dhi
and hi denotes the parameters in the model. For all three models
a logistic regression model was used for the likelihood
P(Datajhi,Hi). The log of the Bayes factor was reported for both
H1 and H2. This method addresses Difficulty 3 to some extent by
considering three values of the genotype. However, it does not
concern multi-locus hypotheses and address Difficulty 4.
Zhang and Liu [24] developed Bayesian epistasis association
mapping (BEAM) for the purpose of discovery. However, the
method does assign prior probabilities to loci being associated with
the disease and reports posterior probabilities. It does not consider
multiple competing hypotheses.
Sebastiani et al. [25] computed the posterior probabilities of
individual SNPs using a likelihood like the one presented here.
These researchers performed a GWAS concerning 298,734 SNPs
with the purpose of developing a system for predicting extended
longevity (EL). In the first stage of their investigation they computed
the posterior probability of each SNP being associated with EL,
where the prior probability was assumed to be 0.5. They used
these posterior probabilities to rank the SNPs and thereby flag
SNPs to include in the second phase of the investigation, which
was to decide which SNPs to include in the predictive model.
Bayesian networks have previously been used to discover disease
loci interactions using likelihoods [10,26–28]. However, we know
of no previous research that used them to determine the posterior
probability of a complex multi-SNP model being associated with
the disease.
Methods
We developed the BNPP method specifically to enable us to
compute the posterior probability of multi-locus models, which
addresses Difficulty 4 above; however, it also attends to the other
three difficulties.
A 1-locus model is the model that a single locus by itself is
associated with a phenotype such as a disease, a 2-locus model is
the model that two loci together are associated with a phenotype,
and so on. The BNPP method represents such models using
particular types of Bayesian network structures and computes the
posterior probability of a model based on the likelihoods of these
structures and their prior probabilities.
The BNPP was designed for the purpose of flagging SNPs for
further investigation; that is, it is intended to compute the posterior
probability of a model that was already discovered or conjectured.
We previously used Bayesian networks for discovery of disease loci
associations [10,26,27]. However, we only computed the likeli-
hoods of the models; we did not consider their prior probabilities.
A bigger model (more loci) will sometimes have a higher
likelihood, but be less probable because of its smaller prior
probability. The BNPP accounts for this situation, whereas a
method that only looks at likelihoods does not. So, the BNPP is
also a new, promising technique for discovery.
Before describing the BNPP algorithm, we first review Bayesian
networks on which the algorithm is based.
A Bayesian Method for Disease Loci Evaluation
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Bayesian Networks
Bayesian networks [14] have been used for modeling and
knowledge discovery in many domains, including applications to
bioinformatics [29]. A Bayesian network (BN) consists of a directed
acyclic graph (DAG) Gwhose set of nodes V contains random
variables and a joint probability distribution P(V ) that satisfies the
Markov condition with G. We say that (G,P) satisfies the Markov
condition if for each variable X[V , it holds that X is conditionally
independent in P of the set of all its nondescendents in G given the
set of all its parents in G. It is a theorem [14] that (G,P) satisfies
the Markov condition (and therefore is a BN) if and only if P is
equal to the product of its conditional distributions of all nodes
given their parents in G, whenever these conditional distributions
exist. That is, if our variables are X1,X2, . . . ,Xn, and PAi is the
set of parents of Xi, then
P(X1,X2, . . . ,Xn)~ P
n
i~1
P(XijPAi):
Due to this theorem, BNs are often developed by first defining a
DAG that satisfies the Markov condition relative to our belief
about the probability distribution of the nodes in the DAG, and
then determining the conditional probability distributions for this
DAG. Often the DAG is a causal DAG, which is a DAG in which
there is an edge from X to Y if and only if X is a direct cause of Y
relative to the other nodes in the DAG.
Figure 1 shows a BN representing the causal relationships
among gene expression levels. The expression levels have been
discretized into two values, low and high. Using this BN, we can
determine conditional probabilities of interest using the BN and a
BN inference algorithm. For example, if a given individual has
C~low and S~high, we can for example determine the
conditional probability of A being low and of D being low. That
is, we can compute
P(A~lowjC~low,S~high)
and P(D~lowjC~low,S~high):
Methods have been developed both for learning the parameters
in a BN and the structure (called a DAG model) from data. The
research discussed here concerns structure learning, which we
discuss next. The task of learning a unique DAG model from data
is called model selection. As an example, if we had data on a large
number of individuals and their expression levels of the genes
shown in Figure 1, we might be able to learn the DAG in Figure 1
from data. When the edges represent causal influences, this means
we can learn causal influences from data under assumptions. In
the score-based structure learning approach, we assign a score to a
DAG based on how well the DAG fits the data.
Cooper and Herskovits [30] developed the Bayesian score for
discrete variables, which is the probability of the Data given the
DAG. This score uses a Dirichlet distribution to represent our
prior belief for each conditional probability distribution in G and
contains hyperparameters that represent these prior beliefs. The
score is as follows:
scoreBayes(G : Data)~P(DatajG)
~ P
n
i~1
P
qi
j~1
C(
Xri
k~1
aijk)
C(
Xri
k~1
aijkz
Xri
k~1
sijk)
P
ri
k~1
C(aijkzsijk)
C(aijk)
,
ð1Þ
where
1. n is the number of variables in the DAG model G;
2. ri is the number of states of Xi;
3. qi is the number of different values that the parents of Xi in G
can jointly assume;
4. aijk is our assessed prior belief from previous experience (before
obtaining the current data) of the number of times Xi took its
kth value when the parents of Xi took their jth value;
5. sijk is the number of times in the data that Xi took its kth value
when the parents of Xi took their jth value.
The Bayesian score does not necessarily assign the same score to
Markov equivalent DAG models. Two DAGs are Markov equivalent
if they entail the same conditional independencies. For example,
the DAGs XRY and XrY are Markov equivalent. Heckerman
et al. [31] show that if we determine the values of the
hyperparameters from a single parameter a called the prior
equivalent sample size then Markov equivalent DAGs obtain the
same score. If we use a prior equivalent sample size a and want to
represent a prior uniform distribution for each variable in the
network, then for all i, j, and k we set aijk~a=riqi, where ri and qi
are defined as above. When we use a prior equivalent sample size
a in the Bayesian score, the score is called the Bayesian Dirichlet
equivalent (BDe) score. When we also represent a prior uniform
distribution for each variable, the score is called the Bayesian
Dirichlet equivalent uniform (BDeu) score and is given by the following
formula, which is a special case of Equation 1:
P(DatajG)~scorea(G : Data)
~ P
n
i~1
P
qi
j~1
C(a=qi)
C(a=qiz
Pri
k~1 sijk)
P
ri
k~1
C(a=riqizsijk)
C(a=riqi)
:
ð2ÞFigure 1. A Bayesian network showing possible relationships
among gene expression levels. The levels have been discretized to
the values low and high. The network is for illustration purposes only; it
is not meant to accurately portray real relationships.
doi:10.1371/journal.pone.0022075.g001
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Posterior Probabilities of Disease-SNP Models
In what follows, for simplicity we refer to variables that might be
associated with a disease as SNPs. However, in general they could
be any genetic information or environmental factors. We can
represent the relationship between a disease and SNPs using
simple DAG models like those shown in Figure 2. The first model
represents that SNP S1 is associated with diseaseD. The third
model represents that SNPs S1 and S3 together are associated with
D (this could happened because each individually is associated
with D or because together they are associated with D due to an
epistatic interaction), and the fourth model represents that SNPs
S4, S6, and S8 together are associated with D.
Our goal is to compute the posterior probability of a model M
given Data. We can do that using Bayes’ Theorem as follows:
P(MjData)~P(DatajM)P(M)
P(Data):
ð3Þ
The P(DatajM) term can be computed using the BDeu score
(Equation 2) with a particular choice of a. The BDeu score has
been used successfully to learn epistatic interactions from real
GWAS data sets, and in one analysis [26] it has been shown to
more often identify the model generating the data than
multifactor-dimensionality-reduction (MDR) [32], a well-known
method for learning epistatic interactions. The P(M) term is the
prior probability of M. We discuss the assessment of this
probability in Supporting Information S1. We call the posterior
probability in Equation 3 the Bayesian Network Posterior Probability
(BNPP). Next we show how to compute the BNPP.
Computing the BNPP
Consider first a 1-SNP model. Let Mi be the model that Si all by
itself is associated with D and M0 be the model that it is not (see
Figure 3). Then the posterior probability of Mi is given by
P(MijData)~ P(DatajMi)P(Mi)
P(DatajMi)P(Mi)zP(DatajM0)P(M0) : ð4Þ
Note that the model in Figure 3 is not just that Si is associated with
the disease, but rather that it is associated all by itself. That is, if Si
was involved in an epistatic interaction with no marginal effects,
the model would be false. Note further that Si can have any
number of discrete values in the model. We are not restricted to
only two values as in some of the methods discussed previously. So
we can represent all three values of a SNP, or if we are
representing an environmental feature with many values we can
represent all of them. If the environmental feature is continuous,
we can discretize it. So we overcome Difficulty 3 mentioned in the
introduction (recall that Difficulty 3 is that the odds ratio only
considers two possibilities, either a condition is present or it is not).
Figure 4 shows the model Mij that Si and Sj together are
associated with D (without needing other interacting SNPs). Note
that this model includes the possibility that there is epistasis with
no marginal effects, as well as the possibility that each SNP by itself
has an association with D. The three competing models are on the
right. Note further that the model denoted as Mi is not the same as
the model Mi in Figure 3. Model Mi in Figure 4 represents that Sj
is not associated with D either by itself (other than possibly
through Si) or together with Si, whereas model Mi in Figure 3 says
nothing about Sj .
No other method discussed in the introduction considers these
multiple competing hypotheses. They would only consider the null
hypothesis M0 in which no association with D holds versus Mij .
However, if either model Mi or Mj were the correct model, we
would observe an association of the two SNPs together with D
(and therefore reject M0) even though Mij is incorrect. An
example of this situation is the relationship between APOE and
rs41377151, which will be discussed when we analyze an
Alzheimer’s data set in the Results section. So we attend to
Difficulty 4 mentioned in the introduction (recall that Difficulty 4
is that other methods only consider a null hypothesis and an
alternative hypothesis).
The posterior probability of Mij is as follows:
P(Mij jData)~
P(DatajMij)P(Mij)
P(DatajMij)P(Mij)zP(DatajM0)P(M0)z
P
k P(DatajMk)P(Mk)
,
where k sums over the two 1-SNP models.
Figure 5 shows a 3-SNP model and the competing models. The
number and complexity of the competing models increases with
the size of the model. However, we need not identify all the
competing models because we have developed the following
recursive algorithm for computing P(Data) for an arbitrary
number of SNPs, which is the denominator in the formula for the
posterior probability of a model:
Algorithm: Compute P(Data).
The SNPs in the model being evaluated are S1, S2,…., Sn.
prior½m is the prior probability of an m-SNP model.
Figure 2. DAG models representing associations between SNPs
and a disease.
doi:10.1371/journal.pone.0022075.g002
Figure 3. The model that Si is associated with D all by itself is on
the left and the model that it is not is on the right.
doi:10.1371/journal.pone.0022075.g003
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We assume all m-SNP models have the same prior probability,
but this assumption is not necessary.
P(Data)~0;
for m~0 to n
likelihood~0;
M~1;
ComputeLikely(1,m);
P(Data)~P(Data)zlikelihood|prior½m;
endfor
procedure ComputeLikely(k,m) // m is the size of the model
being considered.
if m~0
likelihood~likelihoodzP(DatajM); // likelihood and M are
global to this procedure.
else
for i~k to n{mz1
add Si to M;
ComputeLikely(iz1,m{1);
remove Si from M;
endfor
endif
There are n SNPs in the model being analyzed. The algorithm
proceeds by calling procedure Computelikely for every m#n. For
each value of m this routine then computes the contribution of all
m SNP models to the likelihood by recursively visiting all such
models. Since every subset of the n SNPs determines a competing
model, the likelihoods for 2n models are computed. However, since
ordinarily there are at most 5 SNPs in a model, this computation is
feasible.
There are various possibilities for the data structure we could
use in representing a model. We currently choose to represent a
model simply as an n-element array M, where M[i] contains the
index of the ith SNP in the model. For example, if n= 3 and S2, S4,
and S10 are the SNPs in the model, then M[1] = 2, M[2] = 4, and
M[3] = 10.
Results
Next we present results of evaluating the BNPP using both
simulated and real data sets. All experiments were done using a
Figure 4. The model that Si and Sj together are associated with D is on left; the three competing models are on the right.
doi:10.1371/journal.pone.0022075.g004
Figure 5. A 3-SNP model and its competing models.
doi:10.1371/journal.pone.0022075.g005
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Macbook Pro notebook with a 2.66 GHz processor and 8 GB of
RAM. For the sake of focus, in what follows we will always refer to
the phenotype as a disease.
Simulated Data
Velez et al. [33] created 70 epistasis models that are described in
Supplementary Table one to that paper. Each model represents a
probabilistic relationship in which two SNPs together are
statistically associated with the disease, but neither SNP is
individually predictive of disease. The relationships represent
various degrees of penetrance, heritability, and minor allele
frequency. Data sets were generated with case-control ratio of
1:1. To create one data set they fixed the model. Based on the
model, they then generated data concerning the two SNPs that
were related to the disease in the model, 18 other unrelated SNPs,
and the disease. For each of the 70 models, 100 data sets were
generated for a total of 7000 data sets. This procedure was
followed for data set sizes equal to 200, 400, 800, and 1600.
The data sets were generated separately. See http://discovery.
dartmouth.edu/epistatic_data to obtain these data sets.
For each of these data sets, we computed the posterior
probability of each 1-SNP, 2-SNP, and 3-SNP model using the
BNPP, making a total of 1350 models investigated per data set. As
discussed in Supporting Information S1, researchers estimate that
in an agnostic study the prior probability of an individual SNP
being associated with a disease is between 0:0001 and 0:00001. An
agnostic study is an explorative study in which we have no special
prior belief concerning any particular locus. Lower and upper
posterior probabilities were obtained using each of these priors for
an individual SNP being associated with a disease, and using the
strategy for determining model priors based on individual SNP
priors, which is also presented in Supporting Information S1. To
compute the likelihoods the BDeu score (Equation 2) was used.
The hyperparameter a was set equal to 54 because this value
yielded good epistasis discovery in a previous study [27] using the
Velez and other data.
Table 1 shows the results. The average probability of the true
models is much higher than that of the false models. Furthermore,
this average probability is moving toward 1 as the sample size
increases, whereas that of the false models remains quite small.
Finally, the results for the two different priors are not substantially
different. This robustness result is encouraging because the
assessment of priors is arguably the most onerous part of a
Bayesian analysis.
We repeated the analysis using p-values obtained from Pearson’s
chi-square test. Table 2 shows the results. These p-values are
uncorrected since a Bonferroni or Sˇida´k correction would be the
same for all of them, and therefore not change the relative order.
Notice that the average p-value of the best false models is smaller
than that of the true models (recall that smaller p-values are more
significant). Table 1 shows that the average posterior probability of
the best false models is smaller than that of the true models (larger
posterior probabilities are more significant).
The performance of an evaluation method can be judged by
how high it ranks true models and how low it ranks false models.
The previous results support that the BNPP algorithm exhibits
better evaluation performance than the method based on p-values.
Next we address discovery. Figure 6 shows ROC curves
concerning the posterior probabilities when the individual SNP
prior is 0:00001 and the p-values for the simulated data sets. The
results for the posterior probabilities were almost identical when
the prior was 0:0001; so we do not show them. A receiver operating
characteristic (ROC) curve plots the true positive rate (sensitivity) on
the y-axis and the false positive rate (1 - specificity) on the x-axis. It
is obtained by considering various threshold probabilities as being
binary indicators of discovery. For example, the point
(0:014, 0:449) appears on the curve for the posterior probability
in Figure 6 (a) because 0:014 fraction of the false models have
posterior probabilities exceeding a threshold (in this case
2:95|10{7), while 0:449 fraction of the true models have
posterior probabilities exceeding this threshold. The point
(0:16, 1:0) appears on the curves in Figures 6 (a), (b), and (c)
and the point (0:13, 1:0) appears on the curve in Figure 6 (d). This
means that if we were using the posterior probability as a binary
indicator of discovery in the case of samples sizes of 200, 400, or
800, we could discover all the true models with a false discovery
rate of about 16% (based on this analysis). On the other hand, the
true positive rate for the p-value does not reach 1 until the false
positive rate reaches 1. This is true even when the data set has size
1600 (this is not noticeable in the display of its ROC curve). This
result supports the effective discovery performance of the BNPP.
Velez et al. [33] showed that models 55–59 in the Velez Data
are the most difficult models to learn. They have the weakest
broad-sense heritability (0.01) and a minor allele frequency of 0.2.
These models are arguably most like relationships we might find in
nature. ROC curves concerning only these models appear in
Figure 7. Although the curves for the posterior probability are not
that much worse than when we consider all models, the ones for
the p-value are substantially worse except when the sample size is
1600. The worst possible ROC curve is a straight line from (0,0) to
(1,1). The p-value ROC curve when the sample size is 200 is not
much better than that line.
We can perhaps apply different corrections to different sized
models and stay in the framework in which the correction is
applied by arguing that 1-SNP models, 2-SNP models, and 3-SNP
models are different families of models and we should apply
different corrections for each of these families. Since there were 20
SNPs total in the simulations, we applied the Sˇida´k correction
using 20 for 1-SNP models,
20
2
 
~190 for 2-SNP models, and
20
3
 
~1140 for 3-SNP models. The resultant curves appear
with a dotted line in Figure 7. Although we have improved the
results, they are still not as good as those for the posterior
probability. Also, if we did a study with a different number of
SNPs, we would need to apply a different correction, and we
would expect to obtain different results. On the other hand, the
BNPP model suggests using the same prior probabilities across all
agnostic studies.
The average times to compute the posterior probabilities and
the p-values for all one to three SNP models were 1.8 seconds and
0.7 seconds respectively.
Real Data
Alzheimer’s Data set. Reiman et al. [3] analyzed a GWAS
late onset Alzheimer’s disease (LOAD) data set on 312,317 SNPs
from an Affymetrix 500K chip, plus the measurement of a locus in
the APOE gene, which is known to be predictive of LOAD. The
data set consists of three cohorts containing a total of 1411
participants. Of the 1411 participants, 861 had LOAD and 550
did not. In addition, 644 participants were APOE e4carriers, who
carry at least one copy of the APOE e4 genotype and 767 were
APOE e4 non-carriers. See http://www.tgen.org/neurogenomics/
data concerning this data set. Reiman et al. found the APOE gene
is significantly associated with LOAD, the GAB2 gene is not
significantly associated with LOAD, the GAB2 gene is significantly
associated with LOAD in APOE e4 carriers, and the GAB2 gene is
not significantly associated with LOAD in the APOE e4 non-
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carriers. These results indicate that APOE and GAB2 may interact
epistatically to affect LOAD. Using these same data, we computed
the posterior probability of each locus being associated with
LOAD (1-locus models), and the posterior probability of each
locus together with APOE being associated with LOAD (2-locus
models).
The average posterior probability of all 1-locus models was
2:85|10{5 for the individual SNP prior equal to 0.0001, and
9:18|10{6 for that prior equal to 0.00001. Furthermore, the
numbers of models (loci) with posterior probabilities less than
0.01 were respectively 312,301 and 312,273 for the two priors.
Figure 8 shows bar charts depicting the results concerning the
remaining loci. Table 3 shows the loci in the 10 most probable
models. APOE has a posterior probability of ,1, regardless of the
prior, as does SNP rs41377151. SNP rs41377151 is on the
APOC1 gene, which is in strong linkage disequilibrium with APOE
and for which previous studies have indicated that they predict
LOAD equally well [34]. The 3rd most probable locus is
rs1082430, which is on the PRKG1 gene. There are a number of
previous studies associating this gene with LOAD [35,36]. Of the
seven remaining probable loci, there is some previous evidence
linking four of them to LOAD [37].
As mentioned in Supporting Information S1, as more genome-
wide association studies are carried out we will better be able to
assess appropriate priors. These results indicate that 0.00001 may
be more appropriate than 0.0001 since the latter prior resulted in
fairly high posterior probabilities for three SNPs that have no
known previous association with LOAD; nonetheless, these might
be valid predictors of LOAD that have not been appreciated
previously.
The average posterior probability of all 2-locus models, in which
one of the loci was APOE, was 1:05|10{4 for the individual SNP
prior equal to 0.0001 and 1:41|10{5 for that prior equal to
0.00001. Furthermore, the numbers of models with posterior
probabilities less than 0.01 were respectively 312,267 and 312,028
for the two priors. Figure 9 shows bar charts depicting the results
concerning the remaining models. Table 4 shows the loci in the
ten most probable models. Eight of those loci are SNPs located on
the GAB2 gene. The prior probability of a 2-SNP model is
6610210 when the individual SNP prior is 0.0001 and 6610212
when that prior is 0.00001 (See Supporting Information S1). We
see from Table 4 that the posterior probabilities of 2-locus models
containing APOE and a GAB2 SNP are much greater than these
prior probabilities. On the other hand, the 1-locus models
containing GAB2 SNPs had posterior probabilities about equal
to their prior probabilities. These results together indicate GAB2
by itself does not affect LOAD, but that GAB2 interacts with APOE
to affect LOAD.
The two loci in the top ten 2-locus models that are not on GAB2,
namely SNPs rs6784615 and rs12162084, are among the 10 most
probable 1-locus models (see Table 3). These results together
indicate that each of these SNPs may affect LOAD independently
of APOE. As indicated in Table 3, previous studies have associated
these SNPs with LOAD.
Another interesting result is that APOE and rs41377151 (the two
loci with posterior probabilities about equal to 1 in Table 3), when
considered together, had posterior probabilities of 1:25|10{4
and 1:25|10{5 for the individual SNP priors of 0.0001 and
0.00001 respectively. This result indicates that the model
containing both loci is incorrect. As mentioned above, SNP
Table 1. The posterior probability results for the simulated data sets.
prior
probability
sample
size
times true model
was highest
avg. posterior probability
of true models
avg. posterior probability
of best false models
avg. posterior probability
of all false models
0:00001 200 2783 0:2009 4:5|10{4 4:5|10{7
0:00001 400 4265 0:4555 0:0019 1:72|10{6
0:00001 800 5433 0:6502 0:0053 4:62|10{6
0:00001 1600 6191 0:8128 0:0069 5:72|10{6
0:0001 200 3135 0:2651 0:0036 3:85|10{6
0:0001 400 4549 0:5024 0:0095 9:27|10{6
0:0001 800 5580 0:6910 0:0136 1:32|10{5
0:0001 1600 6298 0:8351 0:0134 1:25|10{5
The 1st column shows whether the smaller or larger priors were used; the 3rd column shows the number of times (out of 7000 data sets) the true (i.e., the data-
generating) model had the highest posterior probability; the 4th column shows the average posterior probability of the true models; the 5th column shows the average
posterior probability of the most probable false models (in each of the 7000 data sets); and the last column shows the average posterior probabilities of all false models.
doi:10.1371/journal.pone.0022075.t001
Table 2. The p-value results for the simulated data sets.
sample size avg. p-value of true models avg. p-value of best false models avg. p-value of all false models
200 0:0605 0:0026 0:478
400 0:0271 0:0011 0:4829
800 0:0083 3:92|10{4 0:486
1600 0:0012 7:87|10{5 0:487
The values are like those in Table 1 except they concern the p-values obtained using Pearson’s chi-square test.
doi:10.1371/journal.pone.0022075.t002
A Bayesian Method for Disease Loci Evaluation
PLoS ONE | www.plosone.org 8 August 2011 | Volume 6 | Issue 8 | e22075
rs41377151 is on the APOC1 gene, and previous investigations
have shown that APOE and APOC1 are in linkage disequilibrium
and each of them predicts LOAD as well as the other [34].
However, we know of no previous study substantiating that the
two loci identify the same single causal mechanism of LOAD. This
result could not have been obtained with a method that only
considered the null hypothesis that the two loci together are not
associated with LOAD, and the alternative hypothesis that they
are. For example, using Pearson’s chi-square test, we obtained p-
values all equal to ,0 for APOE alone, rs41377151 alone, and
APOE and rs41377151 together (the 2-locus model). The BNPP
determined that the 2-locus model is improbable because it also
evaluated the competing hypotheses that only one locus is directly
causative of LOAD. To learn that the 2-locus model is not
significantly better than the 1-locus model using commonly
applied frequentist statistics, we would need to perform an analysis
such as stepwise regression or regression on the two loci followed
by an investigation of the coefficients.
The three interesting results just discussed (the first concerning
GAB2, the second rs6784615 and rs12162084, and the third
rs41377151) follow from our computing the posterior probabilities
of all 1-locus models and all 2-locus models containing APOE. It
was not necessary to suspect any of them ahead of time or perform
a focused analysis.
The running times were 196 seconds and 193 seconds to
investigate all 312,318 1-locus models using individual SNP priors
0.0001 and 0.00001, respectively. The corresponding running
times to investigate all 2-locus models containing APOE were
593 seconds and 584 seconds.
Breast Cancer Data set. Hunter et al. [1] conducted a
GWAS concerning 546,646 SNPs and breast cancer as part of
the National Cancer Institute Cancer Genetic Markers of Susceptibility
(CGEMS) Project. (see http://cgems.cancer.gov/.) They deter-
mined the significance of each SNP using logistic regression with
two degrees of freedom. Two of the six most significant SNPs were
on the FGFR2 gene. Furthermore, two other FGFR2 SNPs were
among the 16 most significant SNPs. Previously, it was known that
FGFR2 is amplified and overexpressed in breast cancer [38,39].
Furthermore, a large, three-stage GWAS of breast cancer had
identified SNPs in FGFR2 as the strongest of its associations [2].
Figure 6. ROC curves concerning the posterior probabilities when the prior is 0.00001 and the p-values for the simulated data sets.
The curve for the posterior probability is a solid line, while the one for the p-values is a dashed line. 1-specificity is on the x-axis and the sensitivity is
on the y-axis.
doi:10.1371/journal.pone.0022075.g006
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Figure 7. ROC curve concerning the posterior probabilities when the prior is 0.00001 and the p-values for models 55–59. The curve
for the posterior probability is a solid line, the one for the p-value is a dashed line, and the one for the p-value with the Sˇida´k correction is a dotted
line. 1-specificity is on the x-axis and the sensitivity is on the y-axis.
doi:10.1371/journal.pone.0022075.g007
Figure 8. Bar charts showing the number of 1-locus models in each posterior probability range. The posterior probability is that of the
model in which a single locus is associated with LOAD.
doi:10.1371/journal.pone.0022075.g008
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Based on their results and these previous findings, Hunter et al. [1]
investigated FGFR2 in three additional studies and found further
support for an association of FGFR2 with breast cancer.
Using this same GWAS data set, we computed the posterior
probability of all 1-locus models using the agnostic individual SNP
priors of 0.00001 and 0.0001 and the informative priors of 0.01 and
0.1. The average posterior probability of all 1-locus models was
3:81|10{7 for the prior equal to 0.00001 and 3:78|10{6 for the
prior equal to 0.0001. Furthermore, the numbers of models (loci)
with posterior probabilities less than 0.01 were respectively 546,645
and 546,637 for the two priors. Table 5 shows results concerning the
ten most probable models. Columns 2–5 show posterior probabil-
ities while Columns 6 and 7 show p-values and Sida´k-corrected p-
values. The six most significant SNPs discovered by Hunter [1] are
in our ten most probable models. These are the SNPs for which we
show p-values, which were obtained from [1]. However, we
performed the Sida´k-correction as this was not done in [1].
If we consider a result significant based on the Sˇida´k correction,
no result would be close to significant and the findings in this study
would not support any of the SNPs being predictive of breast
cancer. Given the considerable prior knowledge concerning
FGFR2, we can follow a practice established in Wacholder et al.
[12] of assigning a prior probability of 0.01 to 0.1 to an FGFR2
SNP. Using even the smaller of these priors, our Bayesian analysis
of these data strongly supports that FGFR2 is associated with breast
cancer. Hunter et al. [1] drew a similar conclusion without
performing a formal analysis involving priors. We had no prior
belief that SNP rs10510126 was associated with breast cancer, and
Hunter et al. [1] did not discuss this SNP further, even though it
had the smallest p-value. However based on our priors for an
agnostic search, the posterior probability of this SNP is between
0.0118 and 0.1185, and is much larger than any of the other
posterior probabilities. Based on this result and the utility of
further analysis (see the Conclusions section), this SNP appears to
warrant additional study.
Besides the three FGFR2 SNPs, three other SNPs in the top ten
have been previously associated with breast cancer [40,41]. See
Table 5.
A Comparison to the FPRP. Kuschel et al. [42] investigated
16 SNPs in seven genes involved in the repair of double-stranded
DNA breaks and breast cancer in a case-control study involving
2200 cases and 1900 control subjects. Using standard significance
testing, they found two polymorphisms in XRCC3 and one
polymorphism in each of XRCC2 and LIGA to be the most
significant. They also performed a haplotype analysis investigating
the effect of the genetic variants in the XRCC3 gene on breast
cancer. Wacholder et al. [12] analyzed these same data using the
FPRP method. Statistical power in their analysis was the power to
detect an odds ratio of 1.5 for the homozygote with the rare
genetic variant and an odds ratio of 1.0 for the homozygote with
the common variant. Based on previous findings [40,41],
Wacholder et al. [12] assigned a prior range of 0.01 to 0.1.
We analyzed these same data using the BNPP algorithm to
obtain the posterior probabilities of the models. Table 6 shows the
results. The last two columns show posterior probabilities of
association with breast cancer; to make comparisons easier, we
show 1-FPRP in columns 3 and 4. The p-values in the second
column were computed using the chi-square test with two degrees
of freedom.
The FPRP and BNPP exhibit similar results concerning the four
SNPs and the haplotype, however, the results for BNPP are more
Table 3. Results concerning the 10 most probable 1-locus
models in the LOAD study in [3].
locus
posterior probability
range
previous LOAD
association
APOE (1, 1) Yes
rs41377151 (1, 1) Yes
rs10824310 (0:124, 0:586) Yes
rs4356530 (0:086, 0:485) No
rs17330779 (0:066, 0:416) Yes
rs6784615 (0:048, 0:335) Yes
rs10115381 (0:027, 0, 222) No
rs12162084 (0:027, 0:217) Yes
rs4862146 (0.024,0.192) No
rs249153 (0.017,0.152) Yes
doi:10.1371/journal.pone.0022075.t003
Figure 9. Bar charts showing the number of models in each posterior probability range. The posterior probability is that of the 2-locus
model in which each locus together with APOE is associated with LOAD.
doi:10.1371/journal.pone.0022075.g009
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conservative. Recall that a particular value of the odds ratio (1.5)
was used for statistical power in the case of the FPRP. A larger
value would result in smaller posterior probabilities. The BNPP
makes no assumptions about a statistic such as the odds ratio; it
only conditions on the models being true. Note that the posterior
probabilities (using both the FPRP and BNPP) for the LIG4 SNP
are somewhat larger than those for XRCC2 SNP even though the
latter SNP has a smaller p-value. Wacholder et al. [12] discuss how
this result may be due to the fact that there is very little data
concerning the rare homozygote in the case of the XRCC2 SNP.
A Decision Analytic Approach to Using the BNPP
The question remains as to what to with BNPP results. In an
agnostic GWAS investigation the prior probabilities are ordinarily
very low. So, given the limited number of samples in current
GWAS data sets, often the posterior probabilities of even our most
probable models are not very high. For example, consider the
result in Table 5 that the posterior probability of rs10510126 being
associated with breast cancer is either 0:0118 or 0:1185 depending
on whether the prior probability is 0:00001 or 0:0001. The
average of these values, namely 0:0652, can be used to represent
our posterior belief in the validity of this association. This value is
not very high, and so one may ask whether it is significant. In
general, statistics cannot tell us whether a result is significant; it can
only change our belief. It has become a controversial practice by
some to consider a p-value of 0:05 or smaller to be significant
largely because of R.A. Fisher’s [43] statement in 1926 that ‘‘it is
convenient to draw the line at about the level at which we can say:
Either there is something in the treatment, or a coincidence has
occurred such as does not occur more than once in twenty trials.’’
However, as has been often discussed, there is nothing special
about the value 0:05 for a p-value that enables a dichotomous
announcement, just as there is nothing special about a particular
posterior probability.
The value 0:0652 represents our belief concerning the truth of
the model based on our knowledge concerning the model,
namely our prior belief and the data. Although we cannot
dichotomously announce whether the value is significant, we
can use it to make a decision about what to do. We should
report the finding concerning model M if the expected utility of
not reporting M is less than the expected utility of reporting M.
Let UTD be the utility of a true discovery, which is the utility of
reporting a true model, UFD be the utility of a false discovery,
which is the utility of reporting a false model (and which is
therefore negative), UTND be the utility of a true non-discovery,
which is the utility of not reporting a false model, and UFND be
the utility of a false non-discovery, which is the utility of not
reporting a true model (and which is therefore negative). We
should report model M if
UFND(P(MjData)zUTND(1{(P(MjData))
vUTD(P(MjData)zUFD(1{(P(MjData))
or
UTND{UFD
UTD{UFND
v P(MjData)
1{P(MjData)~Odds(MjData): ð5Þ
In the current analysis, Odds(MjData)~0:0652=(1{0:0652)~
0:0697. So we should report the finding (and therefore investigate
the model further) if (UTND{UFD)=(UTD{UFND)v0:0697.
If we take this decision-analytic approach to using the BNPP, we
conclude that it provides researchers with a useful tool for guiding
how they should proceed based on their findings.
Table 5. Results concerning the ten most probable models in the breast cancer study in [1].
SNP prior = 0.00001 prior = 0.0001 prior = 0.01 prior = 0.1 p-value Sˇida´k previous BC association
rs10510126 0.0118 0.1185 0.9967 0.9992 2:4|10{6 0.7307 No
rs17157903 0.0031 0.0306 0.9693 0.9968 8:8|10{6 0.9919 Yes
rs2420946 (FGFR2) 0.0022 0.0218 0.9570 0.9955 1:5|10{5 0.9997 Yes
rs1219648 (FGFR2) 0.0021 0.0209 0.9552 0.9953 1:2|10{5 0.9986 Yes
rs7696175 0.0013 0.0131 0.9298 0.9925 1:5|10{5 0.9997 Yes
rs197275 0.0012 0.0123 0.9256 0.9920 Not Avl. Not Avl. No
rs12505080 0.0012 0.0123 0.9255 0.9920 8:1|10{6 0.9881 No
rs210739 0.0011 0.0114 0.9204 0.9914 Not Avl. Not Avl. Yes
rs10779967 0.0011 0.0113 0.9194 0.9913 Not Avl. Not Avl. No
rs2981579 (FGFR2) 0.0008 0.0083 0.8933 0.9882 Not Avl. Not Avl. Yes
Columns 2–5 show posterior probabilities for various priors, while Columns 6 and 7 shows p-values (obtained from [1]) and Sida´k-corrected p-values.
doi:10.1371/journal.pone.0022075.t005
Table 4. Results concerning the ten most probable 2-locus
models, where one locus is APOE, in the LOAD study in [3].
locus posterior probability range GAB2
rs1007837 (0:266, 0:784) Yes
rs7101429 (0:214, 0:731) Yes
rs901104 (0:201, 0:715) Yes
rs4291702 (0:139, 0:617) Yes
rs4945261 (0:144, 0:564) Yes
rs12162084 (0:144, 0:563) No
rs7115850 (0:108, 0:547) Yes
rs10793294 (0:099, 0:523) Yes
rs2450130 (0:088, 0:491) Yes
rs6784615 (0.081, 0.462) No
doi:10.1371/journal.pone.0022075.t004
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Wakefield [13] proposed a formula similar to Equation (5), but
only considered the UFD and the UFND. That is, the utilities of a
true discovery and of a true non-discovery were not factored into
the decision.
Discussion
We identified four difficulties with many current methods for
computing the posterior probability of a model analyzed using a
GWAS data set. Most importantly, they only consider a null
hypothesis H0 and an alternative hypothesis H1. So, they cannot
handle a complex multi-locus hypothesis which has several
competing hypotheses. Yet it is becoming increasingly common-
place to investigate multi-locus hypotheses. We developed the
BNPP method which enables us to compute the posterior
probability of such hypotheses, and which also attends to the
other difficulties. We illustrated its effectiveness by applying it to
both simulated and real data sets. We showed how the BNPP can
be used to obtain a decision analytic solution as to when to report
a finding.
The greatest difficulty in most Bayesian analyses is arguably the
assessment of prior probabilities. The early rejection and now the
slow acceptance of the Bayesian approach has been due in large
part to the perceived arbitrary nature of these assessments. For
example, in 1921 R.A. Fisher [44] stated that ‘‘The Bayesian
approach depends upon an arbitrary assumption, so the whole
method has been widely discredited.’’ However, the Bayesian
approach does provide an elegant and general solution to the
multiple hypothesis testing problem. Let p1 denote the prior
probability that the model is correct. Wakefield [13] points out
that ‘‘as more genome-wide association studies are carried out
lower bounds on p1~1{p0 will be obtained from the confirmed
‘hits’ - it is a lower bound since clearly many non-null SNPs for
which we have low power of detection will be missed.’’ We agree
that in time results will help us to determine priors. However, one
avenue of research that builds on the results presented here, would
be to hasten this process by performing a comprehensive literature
search to investigate current beliefs concerning agnostic priors.
Supporting Information S1 proposes initial prior probabilities
based on beliefs reported in two articles.
The BNPP was designed for the purpose of flagging SNPs for
further investigation; that is, it is intended to compute the posterior
probability of a model that was already discovered or conjectured.
However, as mentioned at the beginning of the Methods section,
the BNPP is also a promising technique for loci-disease association
discovery. Indeed, in order to illustrate the effectiveness of the
BNPP we showed results in which it was used for discovery. Future
research can further investigate its discovery capability and
compare its performance to other related discovery methods such
as those appearing in [10,24,26–28].
An immediate plan we have for using the BNPP is the following.
We will expand our previous work on discovery to develop a
system that outputs likely one to five SNP models in the first stage.
The BNPP will then be used in the second stage to compute the
posterior probability of each model consisting of a subset of the
SNPs from each of these models. The most probable models will
be reported. This method will be compared to using the BNPP
directly for discovery.
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